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Clinical utility of genetic and genomic services: context matters
W. David Dotson, PhD1, M. Scott Bowen, MPH1, Katherine Kolor, PhD, MS1, and Muin J. 
Khoury, MD, PhD1
1Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia, 
USA
Should diagnoses, and corresponding changes in disease management, be sufficient 
demonstration of clinical utility, even in the absence of evidence for improved clinical 
outcomes? This question is posed to the health-care payer community in a recent American 
College of Medical Genetics and Genomics (ACMG) position statement on the clinical 
utility of genetic and genomic services.1 Affirmative arguments could be drawn from 
examples of individually rare, highly penetrant, single-gene disorders. We fully support the 
ACMG’s call for inclusion of individual, familial, and societal levels of impact in the 
evaluation of testing. Nevertheless, broadening the definition of clinical utility for all cases 
may be less helpful in the evaluation of genetic tests than promoting more context-dependent 
and transparent decision-making, with less rigidity and dogmatic adherence to artificial logic 
models.
 CLINICAL UTILITY
In the statement, the ACMG reports that “coverage decision-making policy is now driven by 
a narrowed perspective that clinical benefit accrues only to the individual receiving the 
services,” so neither etiological diagnosis nor changes in treatment that lack corresponding 
proven health-outcome benefit qualify as demonstration of clinical utility.1 Furthermore, 
familial and societal level benefits are ignored.1 To exemplify a narrow view of clinical 
utility, the ACMG1 cites the MolDX Clinical Test Evaluation Process,2 which is based on 
the Analytic Validity, Clinical Validity, Clinical Utility, Ethical, Legal, Social Implications 
(ACCE) model process.3 Although ACCE was not the first to characterize clinical utility in 
terms of health outcomes, it established a nested model in which clinical utility 
encompasses, and adds to, all other components assessed.
In addition to MolDX, groups such as the Evaluation of Genomic Applications in Practice 
and Prevention (EGAPP) Working Group (EWG),4 the Secretary’s Discretionary Advisory 
Committee on Heritable Disorders of Newborns and Children,5 and the United Kingdom 
Genetic Testing Network6 have drawn on their own interpretations of ACCE, along with 
other sources, in developing methods for evaluation. Although the EWG used ACCE as an 
aid in organizing and better understanding questions for evaluation, they also leveraged the 
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inherent flexibility of the model to create and customize their methods and outcome 
definitions.4,7
The Centers for Disease Control and Prevention’s Office of Public Health Genomics 
founded the EGAPP initiative in 2004 and launched the EWG as an independent panel in 
2005. As early as 2009, published EGAPP methods suggested consideration of information 
that may be helpful in personal decision making and for ending diagnostic odysseys in 
evaluating the clinical utility of tests used in clinical diagnostic scenarios.4 The following 
year, the EWG published its framework for considering relevant outcomes in four categories 
of impact: (i) diagnostic thinking/health information, (ii) therapeutic choice, (iii) patient 
outcome, and (iv) familial/societal.8 Likewise, the methods of the Secretary’s Discretionary 
Advisory Committee on Heritable Disorders of Newborns and Children stipulate that, in 
addition to reductions in morbidity and mortality, “Broader benefits to the individual infant, 
such as nonclinical interventions or benefits to family and community, such as avoiding a 
diagnostic odyssey or informing nonmedical decision making, may also be considered” in 
assessing clinical utility.5
 USING CONTEXTUAL AND OTHER KEY FACTORS
To broaden the definition of clinical utility in a meaningful way, both benefits and potential 
harms at the individual, familial, and societal levels would need to be assessed. The 
weighting of these types of broader outcomes is often not amenable to quantitative 
description or analysis. Instead, these elements may sometimes be presented qualitatively, as 
important considerations or contextual factors. Nevertheless, the potential weight of familial 
and societal impact by the EWG was demonstrated in its 2009 recommendation that all 
patients with newly diagnosed colorectal cancer be tested for Lynch syndrome, to benefit 
family members through cascade screening.8 Potential benefits to family members include 
clear, “hard” outcomes of reduced morbidity and mortality, whereas individual-level benefits 
to patients are not as discernible (at least, based on the evidence considered). With 
recommended testing of individual patients as a means to improve outcomes in relatives, it 
follows that familial and societal level values would necessarily have been influential 
factors. The EWG reported the following as key contextual issues: consideration of potential 
for distress and related psychosocial outcomes following testing, intervention uptake and 
surveillance rates among relatives, and limitations in patient-level benefit; the last issue has 
been reported to have directly influenced the group’s recommendation for informed consent 
antecedent to immunohistochemistry and microsatellite instability testing.8
This recommendation represents a particularly complex clinical scenario, and it is 
noteworthy that EGAPP methods allow for different approaches to assessing clinical utility 
based on how the test is to be used (i.e., diagnostic, screening, prognostic, risk assessment, 
or pharmacogenomics scenarios).4 While testing would be diagnostic of Lynch syndrome for 
patients, for family members testing the colorectal cancer (CRC) patient would fall under the 
category of risk assessment. If the clinical scenario had involved screening for Lynch 
syndrome among people with a family history of CRC or diagnostic application of testing to 
the patient alone, then a different recommendation might result. Consideration of how 
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testing is to be applied can be an important determinant of how clinical utility is assessed 
and therefore whether an actionable recommendation can be made.
 GOING BEYOND CLINICAL UTILITY
Elements of clinical utility in the ACCE model extend beyond clinical effectiveness of 
interventions.3 The EWG has acknowledged viewing many ACCE elements pertaining to 
testing implementation (such as availability of appropriate facilities and educational 
materials) as “information that should not be included in the consideration of clinical utility, 
but may be considered as contextual factors in developing recommendation statements.”4 
Assessing clinical utility in its Lynch syndrome recommendation, the EWG created a chain 
of indirect evidence consisting of assessments of studies showing alteration of patient 
management (considering both proband and family members) and the influence these 
changes had on outcomes; they found only “limited but promising evidence suggesting that 
testing can improve outcomes.”7 Together, these findings suggest that, although the EWG 
may take a more restrictive view of clinical utility than described in the ACCE model, in 
some respects the group takes a broader view on contextual issues, and the overall weighting 
of these issues can influence the outcome of recommendations. Rather than considering 
expansion of the definition of clinical utility, it may be more practicable to ask whether 
interventions whose clinical utility is not backed by adequately powered studies directly 
assessing health outcomes can be recommended through evidence-based evaluation 
processes. We believe that the example of the EGAPP Lynch syndrome recommendation 
suggests that the answer is—sometimes—yes. Practice associated with rare disorders, such 
as many inborn errors of metabolism, has also begun to innovate in addressing this question. 
There are frameworks incorporating more practice-based evidence in evaluating 
interventions at the levels of both health care systems and patients, to address shortcomings 
in more traditional evidence-based medicine in this area.9
Widening the scope of contextual and other issues considered in decision making, beyond 
the strict confines of clinical context, is an idea that may already be gaining traction. This 
type of approach could include, for example, utility of information in its own right and 
factors important in local context, such as inequities that increase variability in follow-up 
services. Reporting on exactly how such factors are considered is critical and can be more 
challenging than reporting more quantitatively assessable outcomes. For example, to arrive 
at the EWG Lynch syndrome recommendation, evaluators would have needed to take into 
account the fact that the mechanics of cascade screening remain controversial in terms of 
relative autonomy, privacy, and other issues at familial and societal levels, with different 
approaches in screening-program management potentially affecting the magnitude of 
potential harms.10 From the EGAPP recommendation, however, it is not possible to 
ascertain the influence of each of these variables on the ultimate decisions that were made. 
For the intended purpose of guiding practice, it may be sufficient to state that such factors 
were considered. For the purposes of informing future research and guideline development 
by other groups, more detail on the specific contextual variables considered, along with 
estimated ranges of potential and actual influence on decisions attributable to each of these 
factors, would be useful.
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Instead of broadening definitions, we believe that it would be more helpful for guidelines to 
consistently include and describe consideration of contextual and other relevant issues, 
extending beyond clinical outcomes to factors such as the value of information in planning 
and in preventing additional unnecessary testing. Guidelines should be more specific in 
reporting the extent to which these kinds of issues are allowed to affect final decisions. 
Without this type of transparent reporting on individual decisions, allowing readers to see 
the sometimes messy application of formal methods, we have no reliable basis on which to 
determine the degree to which contextual factors influence results and a poorer ability to 
understand nuances that may be critical in implementing testing strategies. Professional 
societies should promote the rigorous, evidence-based evaluation of health technologies that 
are within their scope of influence while understanding that the results may not tell the 
complete story. In cases in which contextual and other relevant issues can be convincingly 
argued to outweigh clinical outcome–based demonstration of clinical utility, 
recommendations in favor of testing should be acceptable to proponents of evidence-based 
medicine.
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